Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.84Last Year’s EPS
-0.93Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: multiple successful launches (TRYNGOLZA, DAWNZERA), landmark Phase III data (olezarsen, zilganersen), 34% revenue growth in 2025, expanding commercial infrastructure and robust partner progress underpin confident guidance and multibillion-dollar peak potential for key programs. Notable near-term risks and conservatism tempering outlook include guidance assuming a standard sNDA review (delaying broader sHTG sales), expected TRYNGOLZA revenue decline during transition and pricing negotiations, projected non-GAAP operating losses as commercial investments continue, cash use for debt repayment, and binary clinical/regulatory readouts (e.g., HORIZON) that carry execution risk. Overall, positive operational and clinical achievements substantially outweigh these manageable near-term financial and timing risks.Company Guidance
Strong Overall Revenue Growth
Total 2025 revenue of $944M, up 34% year-over-year, driven by growing contributions from marketed medicines and R&D collaborations.
TRYNGOLZA Launch Momentum
TRYNGOLZA generated $108M in 2025 product sales with $50M in Q4, a 56% quarter-over-quarter increase; December was the strongest month of 2025 and payer mix is ~60% commercial / 40% government.
DAWNZERA Early Commercial Traction
DAWNZERA achieved $8M in 2025 product sales from initial launch months; free trial program saw strong participation with 100% conversion to paid therapy to date and reaffirmed peak sales potential >$500M.
Olezarsen Pivotal Outcomes — Breakthrough Data
Olezarsen Phase III (CORE/CORE2) showed up to 72% mean placebo-adjusted fasting triglyceride reductions at 6 months and an 85% reduction in adjudicated acute pancreatitis events; number needed to treat (NNT) of 4 in the highest-risk subgroup; received Breakthrough Therapy designation and sNDA submitted with launch-readiness targeted by June.
Zilganersen Phase III Success and NDA Submission
Zilganersen delivered positive Phase III results demonstrating the first disease-modifying benefit in Alexander disease; NDA submitted in January with anticipated approval and launch in the second half of 2026 and planned expanded access program underway.
Partner Pipeline Progress and Bepirovirsen Readout
Partnered programs produced notable readouts: Bepirovirsen Phase III reported unprecedented functional cure rates for chronic HBV; GSK preparing global regulatory submissions and plans commercialization later this year; multiple partner Phase III readouts expected in 2026 (pelacarsen midyear, CARDIO-TTRansform H2 2026).
Diversified Revenue Streams and Royalties
Commercial products generated $436M (46% of revenue); R&D collaborations generated $508M (54%); royalty revenues increased 11% to $285M, supported by SPINRAZA and growing WAINUA royalties.
Financial Position and Outlook
Projected year-end cash and investments of approximately $1.6B, guidance reflecting ~20% like-for-like revenue increase for 2026 after adjusting for a one-time $280M license fee, and a public goal to achieve cash flow breakeven by 2028.
Commercial Readiness and Field Expansion
Full field organization in place with ~200 field team members hired, trained and deployed; commercial preparations in progress for two more independent launches (sHTG olezarsen and zilganersen) in 2026.
IONS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IONS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $85.45 | $80.93 | -5.29% |
Oct 29, 2025 | $73.57 | $71.88 | -2.30% |
Jul 30, 2025 | $41.48 | $43.37 | +4.56% |
Apr 30, 2025 | $29.81 | $30.71 | +3.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ionis Pharmaceuticals (IONS) report earnings?
Ionis Pharmaceuticals (IONS) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is Ionis Pharmaceuticals (IONS) earnings time?
Ionis Pharmaceuticals (IONS) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IONS EPS forecast?
IONS EPS forecast for the fiscal quarter 2026 (Q1) is -0.84.